Sanofi Total Non-Operating Income/Expense 2012-2026 | SNY
Sanofi annual/quarterly total non-operating income/expense history and growth rate from 2012 to 2026. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
- Sanofi total non-operating income/expense for the quarter ending March 31, 2026 was $-0.097B, a 42.73% decline year-over-year.
- Sanofi total non-operating income/expense for the twelve months ending March 31, 2026 was $-2.772B, a 158.87% increase year-over-year.
- Sanofi annual total non-operating income/expense for 2025 was $-2.844B, a 192.71% increase from 2024.
- Sanofi annual total non-operating income/expense for 2024 was $-0.972B, a 47.53% decline from 2023.
- Sanofi annual total non-operating income/expense for 2023 was $-1.852B, a 811.58% decline from 2022.
|
Sanofi Annual Total Non-Operating Income/Expense (Millions of US $) |
|
|---|---|
| 2025 | $-2,844 |
| 2024 | $-972 |
| 2023 | $-1,852 |
| 2022 | $260 |
| 2021 | $-620 |
| 2020 | $-620 |
| 2019 | $-4,109 |
| 2018 | $-1,030 |
| 2017 | $-819 |
| 2016 | $-1,309 |
| 2015 | $-1,216 |
| 2014 | $-916 |
| 2013 | $-2,093 |
| 2012 | $-989 |
| 2011 | $-3,036 |
|
Sanofi Quarterly Total Non-Operating Income/Expense (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-97 |
| 2025-12-31 | $-2,130 |
| 2025-09-30 | $-219 |
| 2025-06-30 | $-326 |
| 2025-03-31 | $-170 |
| 2024-12-31 | $-619 |
| 2024-09-30 | $-352 |
| 2024-06-30 | $70 |
| 2024-03-31 | $-71 |
| 2023-12-31 | $-1,518 |
| 2023-09-30 | $-198 |
| 2023-06-30 | $-96 |
| 2023-03-31 | $-40 |
| 2022-12-31 | $2,157 |
| 2022-09-30 | $-1,617 |
| 2022-06-30 | $-192 |
| 2022-03-31 | $-89 |
| 2021-09-30 | $-93 |
| 2021-06-30 | |
| 2021-03-31 | $-148 |
| 2020-09-30 | $-65 |
| 2020-03-31 | $-163 |
| 2019-09-30 | $-235 |
| 2019-03-31 | $1 |
| 2018-03-31 | $-70 |
| 2017-12-31 | $-365 |
| 2017-09-30 | $-200 |
| 2017-06-30 | $-150 |
| 2017-03-31 | $-106 |
| 2016-12-31 | $-637 |
| 2016-09-30 | $-326 |
| 2016-06-30 | $-185 |
| 2016-03-31 | $-161 |
| 2015-09-30 | $-249 |
| 2015-06-30 | $-48 |
| 2014-06-30 | $-396 |
| 2013-06-30 | $-840 |
| 2012-06-30 | $-283 |
| 2012-03-31 | $-315 |
| 2011-12-31 | $-1,277 |
| 2011-09-30 | $50 |
| 2011-06-30 | $-722 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |